moleculin.com - MBRX Income before deduction of interest, taxes and amortization

Brandmark of Moleculin Biotech Inc (MBRX)

Moleculin Biotech, Inc. (MBRX) develops agents to overcome cancer cell defenses, including the fight against leukemias via Annamycin technology. The company's EBITDA statistics confirm a lack of operational inflow, as 0.00 is recorded as the baseline value. Current momentum is supported only by legacy capital while developments undergo testing. Meanwhile, the strategy across various tumor types minimizes the risk of investment loss.

MBRX: Moleculin Profit before payment of interest, taxes and amortization 11/23/2025 - 11/12/2026

Moleculin Biotech - analytical breakdowns and key metrics (MBRX)

- market value and analyst target forecast:
Market Price Moleculin Biotech Inc|MBRX - Consensus Target
- issuer market value details:
Market Value Moleculin Biotech|MBRX - Total Company Value
- book capitalization information:
Share Book Value Moleculin Biotech|MBRX - Company Book Value|Market Value to Book Value Ratio moleculin.com|MBRX - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Moleculin Biotech, Inc.|MBRX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Moleculin Biotech Inc|MBRX - Company Aggregate Debts|Debts to Book Capitalization Ratio Moleculin Biotech|MBRX - Company Long-Term Debt|Short-Term Debt Moleculin Biotech|Intermediate Coverage Ratio moleculin.com
- earnings and valuation multiples information:
MBRX - Company Net Income|Future Profit Moleculin Biotech, Inc.|MBRX - Price to Earnings Ratio|Market Cap to Projected Earnings Moleculin Biotech Inc|MBRX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Moleculin Biotech|MBRX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Moleculin Biotech|MBRX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months moleculin.com|MBRX - Earnings growth in current year|Expected net earnings per share growth next year Moleculin Biotech, Inc.
Summary company analytics:Moleculin Biotech, Inc., MBRX
Original product of moleculin.com

The development of innovative oncology platforms by Moleculin Biotech, Inc. (MBRX) requires precise monitoring of cash flows stripped of the impact of depreciation and credit obligations. This metric captures the real operational efficiency of the business, allowing users to track actual liquidity between quarterly reports and assess the funding stability of leukemia drug clinical trials via the EBITDA history on the GURU.Markets platform.

Competitors of Moleculin Biotech, Inc. (MBRX)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (bicycletherapeutics.com)|CytomX Therapeutics, Inc. (CTMX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CATX (Perspective Therapeutics, Inc.)|Profit before payment of interest, taxes and amortization Genelux Corp.|Profit before payment of interest, taxes and amortization MOLN|Operating profit EBITDA ONCY|Operating profit EBITDA lisata.com (LSTA)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)